XML 45 R35.htm IDEA: XBRL DOCUMENT v3.20.2
REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION (Tables)
 9 Months Ended
Sep. 30, 2020
Concentration Risk And Geographic Information [Abstract]  
Schedule of Total Revenues from External Customers and Collaborative Partners by Geographic Region
The following table disaggregates Total Revenues from external customers and collaborative partners by geographic region. Net product revenues by geographic region are based on patient location for the Company’s commercial products, except for Aldurazyme, which is sold exclusively to Sanofi Genzyme (Genzyme) who markets and sells Aldurazyme world-wide. Aldurazyme revenues earned by the Company are included in the U.S. region as the transactions are with Genzyme, whose headquarters is located in the U.S. 
Three Months Ended
September 30,		Nine Months Ended
September 30,
2020201920202019
Total revenues by geographic region:
United States$252,948 $201,874 $729,672 $562,217 
Europe121,158 125,485 375,453 369,585 
Latin America44,064 83,799 141,852 164,132 
Rest of world58,614 49,939 161,361 153,671 
Total revenues$476,784 $461,097 $1,408,338 $1,249,605 
Schedule of Net Product Revenues by Product
The following table disaggregates Net Product Revenues by product. 
Three Months Ended
September 30,		Nine Months Ended
September 30,
2020201920202019
Net product revenues by product:
Vimizim$147,891 $163,466 $401,789 $411,953 
Kuvan123,993 120,524 368,604 340,771 
Naglazyme76,323 94,408 271,585 279,462 
Palynziq46,092 24,142 121,354 55,250 
Brineura25,455 19,840 75,223 46,815 
Firdapse— 5,668 1,316 16,262 
Total net product revenues marketed by the Company$419,754 $428,048 $1,239,871 $1,150,513 
Aldurazyme net product revenues marketed by Genzyme40,987 22,852 $128,945 $73,945 
Total net product revenues$460,741 $450,900 $1,368,816 $1,224,458 
Schedule of Total Net Product Revenues Based on Patient Location
The table below disaggregates total Net Product Revenues based on patient location for products sold directly by the Company, and global sales of Aldurazyme, which is marketed by Genzyme. 
Three Months Ended
September 30,		Nine Months Ended
September 30,
2020201920202019
United States$203,892 $175,127 $582,734 $480,330 
Europe115,548 121,363 360,718 358,041 
Latin America44,064 83,799 141,852 164,132 
Rest of world56,250 47,759 154,567 148,010 
Total net product revenues marketed by the Company419,754 428,048 1,239,871 1,150,513 
Aldurazyme net product revenues marketed by Genzyme40,987 22,852 128,945 73,945 
Total net product revenues$460,741 $450,900 $1,368,816 $1,224,458 
Schedule of Net Product Revenue Concentrations Attributed to Largest Customers The following table illustrates the percentage of the Company’s total Net Product Revenues attributed to the Company’s largest customers for the periods presented. 
Three Months Ended
September 30,		Nine Months Ended
September 30,
2020201920202019
Customer A16 %16 %15 %17 %
Customer B14 %13 %14 %12 %
Customer C11 %10 %12 %11 %
Customer D1 %12 %3 %6 %
Total42 %51 %44 %46 %